Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients

Shigeki Yamada, Hideki Ishii, Hiroshi Takahashi, Toru Aoyama, Yasuhiro Morita, Hirotake Kasuga, Keiko Kimura, Yutaka Ito, Ryo Takahashi, Takanobu Toriyama, Yoshinari Yasuda, Mutsuharu Hayashi, Hideki Kamiya, Yukio Yuzawa, Shoichi Maruyama, Seiichi Matsuo, Tatsuaki Matsubara, Toyoaki Murohara

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background and objectives: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. Design, setting, participants, & measurements: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. Results: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. Conclusions: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.

Original languageEnglish
Pages (from-to)1793-1798
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume5
Issue number10
DOIs
Publication statusPublished - 01-10-2010

Fingerprint

Stroke Volume
Chronic Kidney Failure
Renal Dialysis
Mortality
Left Ventricular Dysfunction
Therapeutics
Echocardiography
Survival
Kaplan-Meier Estimate
Cause of Death
Heart Failure

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Yamada, Shigeki ; Ishii, Hideki ; Takahashi, Hiroshi ; Aoyama, Toru ; Morita, Yasuhiro ; Kasuga, Hirotake ; Kimura, Keiko ; Ito, Yutaka ; Takahashi, Ryo ; Toriyama, Takanobu ; Yasuda, Yoshinari ; Hayashi, Mutsuharu ; Kamiya, Hideki ; Yuzawa, Yukio ; Maruyama, Shoichi ; Matsuo, Seiichi ; Matsubara, Tatsuaki ; Murohara, Toyoaki. / Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. In: Clinical Journal of the American Society of Nephrology. 2010 ; Vol. 5, No. 10. pp. 1793-1798.
@article{ee3f4b95f0a44172b399cdba63a399ac,
title = "Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients",
abstract = "Background and objectives: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. Design, setting, participants, & measurements: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. Results: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1{\%}), 247 (19.7{\%}), 107 (8.5{\%}), 41 (3.3{\%}), and 17 (1.4{\%}) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9{\%} in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1{\%} in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. Conclusions: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.",
author = "Shigeki Yamada and Hideki Ishii and Hiroshi Takahashi and Toru Aoyama and Yasuhiro Morita and Hirotake Kasuga and Keiko Kimura and Yutaka Ito and Ryo Takahashi and Takanobu Toriyama and Yoshinari Yasuda and Mutsuharu Hayashi and Hideki Kamiya and Yukio Yuzawa and Shoichi Maruyama and Seiichi Matsuo and Tatsuaki Matsubara and Toyoaki Murohara",
year = "2010",
month = "10",
day = "1",
doi = "10.2215/CJN.00050110",
language = "English",
volume = "5",
pages = "1793--1798",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "10",

}

Yamada, S, Ishii, H, Takahashi, H, Aoyama, T, Morita, Y, Kasuga, H, Kimura, K, Ito, Y, Takahashi, R, Toriyama, T, Yasuda, Y, Hayashi, M, Kamiya, H, Yuzawa, Y, Maruyama, S, Matsuo, S, Matsubara, T & Murohara, T 2010, 'Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients', Clinical Journal of the American Society of Nephrology, vol. 5, no. 10, pp. 1793-1798. https://doi.org/10.2215/CJN.00050110

Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. / Yamada, Shigeki; Ishii, Hideki; Takahashi, Hiroshi; Aoyama, Toru; Morita, Yasuhiro; Kasuga, Hirotake; Kimura, Keiko; Ito, Yutaka; Takahashi, Ryo; Toriyama, Takanobu; Yasuda, Yoshinari; Hayashi, Mutsuharu; Kamiya, Hideki; Yuzawa, Yukio; Maruyama, Shoichi; Matsuo, Seiichi; Matsubara, Tatsuaki; Murohara, Toyoaki.

In: Clinical Journal of the American Society of Nephrology, Vol. 5, No. 10, 01.10.2010, p. 1793-1798.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients

AU - Yamada, Shigeki

AU - Ishii, Hideki

AU - Takahashi, Hiroshi

AU - Aoyama, Toru

AU - Morita, Yasuhiro

AU - Kasuga, Hirotake

AU - Kimura, Keiko

AU - Ito, Yutaka

AU - Takahashi, Ryo

AU - Toriyama, Takanobu

AU - Yasuda, Yoshinari

AU - Hayashi, Mutsuharu

AU - Kamiya, Hideki

AU - Yuzawa, Yukio

AU - Maruyama, Shoichi

AU - Matsuo, Seiichi

AU - Matsubara, Tatsuaki

AU - Murohara, Toyoaki

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background and objectives: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. Design, setting, participants, & measurements: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. Results: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. Conclusions: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.

AB - Background and objectives: Cardiac failure is directly affected by left ventricular (LV) dysfunction, and particularly LV systolic dysfunction is strongly associated with survival in ESRD patients. The aim of this study was to determine the prognostic value of reduced LV ejection fraction (LVEF) measured at the time of initiation of hemodialysis (HD) in incident HD patients. Design, setting, participants, & measurements: 1254 consecutive ESRD patients who electively started HD therapy were screened by echocardiography within 1 month after its inception. They were divided into five groups according to LVEF levels with a decrease of 0.1 each and were followed up for up to 7 years. Survival was examined with the Kaplan-Meier method and compared using the log-rank test. Results: Among the 1254 patients, LVEF levels ≥0.6, 0.5 to 0.6, 0.4 to 0.5, 0.3 to 0.4, and <0.3 were seen in 842 (67.1%), 247 (19.7%), 107 (8.5%), 41 (3.3%), and 17 (1.4%) patients, respectively. On Kaplan-Meier analysis, 7-year event-free rates from cardiovascular death were 84.2, 83.7, 73.6, 59.4, and 30.9% in order of groups with decreasing LVEF of 0.1 each, respectively. Seven-year event-free rates from all-cause death were 69.2, 61.7, 57.1, 45.9, and 23.1% in the respective groups. Even after adjustment for other risk factors, decreasing LVEF was a strong independent predictor for cardiovascular death. Conclusions: Reduced LVEF on starting HD therapy could stratify risk of cardiovascular and all-cause mortality in ESRD patients. Screening by echocardiography at start of HD therapy might be recommended to predict prognosis in patients with ESRD.

UR - http://www.scopus.com/inward/record.url?scp=77958586326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958586326&partnerID=8YFLogxK

U2 - 10.2215/CJN.00050110

DO - 10.2215/CJN.00050110

M3 - Article

C2 - 20595691

AN - SCOPUS:77958586326

VL - 5

SP - 1793

EP - 1798

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 10

ER -